CFT8634

ArtNr	HY-145925B-5mg
Hersteller	MedChem Express
CAS-Nr.	2704617-96-7
Menge	5 mg
Quantity options	10 mg 1 mg 25 mg 50 mg 5 mg
Kategorie	Reagents & Chemicals Biochemicals
Typ	Chemicals
Specific against	other
Purity	98.10
Citations	[1]Zeng S, et al. Current advances and development strategies of orally bioavailable PROTACs. Eur J Med Chem. 2023 Dec 5;261:115793.\|[2]Jackson, et al. "Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers." Cancer Research 82.12_Supplement (2022): ND09-ND09.\|[3]Poling, et al. "CFT8634, a clinical stage BRD9 Bi DAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide." Blood 142 (2023): 6594.\|[4]Poling, et al. "CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone." Cancer Research 84.6_Supplement (2024): 6046-6046.
Smiles	CC(C(C1=CC(OC)=C(C(OC)=C1)CN2CC(F)([C@@H](N3CCN(C4=C(C=C(C=C4)N[C@@H]5C(NC(CC5)=O)=O)F)CC3)CC2)F)=CN6C)=C(C)C6=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Epigenetic Reader Domain; PROTACs
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	710.79
Product Description	CFT8634 is an orally bioavailable PROTAC BRD9 targeted degrader based on the E3 ubiquitin ligase CRBN mechanism. CFT8634 can be used for the study of synovial sarcoma and SMARCB1-deficient solid tumors (Pink: BRD9 ligand (HY-169988); Blue: E3 ligase ligand (HY-169989); Black: linker (HY-169991). CFT8634 is a heterobifunctional molecule that binds to BRD9 at one end and recruits CRBN at the other end, which can inhibit the growth of tumor cells that depend on BRD9. CFT8634 can be used for the study of SMARCB1-related cancers (such as synovial sarcoma and malignant rhabdoid tumor)[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics; PROTAC
Isoform	Cereblon
Clinical information	Phase 1

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-145925B-5mg-safety-datasheet.pdf